Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
KalVista Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small-molecule protease inhibitors. The company operates within the biopharmaceutical and rare disease sectors, with a primary emphasis on developing oral therapies for conditions with significant unmet medical need. KalVista’s core value proposition is its expertise in designing highly selective plasma kallikrein inhibitors.
The company’s primary revenue drivers are currently research and development activities rather than commercial product sales, as it has not yet achieved sustained product commercialization. KalVista is best known for its lead program targeting hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent swelling attacks. Founded in 2011, the company evolved from a discovery-focused organization into a late-stage clinical developer, advancing its pipeline through multiple clinical trials and strengthening its regulatory engagement with U.S. and international health authorities.
Business Operations
KalVista’s operations are centered on a single reportable segment focused on drug discovery and development, with its pipeline led by sebetralstat, an investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE. The company generates no material commercial revenue and relies primarily on equity financing and strategic capital raises to fund its operations.
Operational activities are conducted across the United States and United Kingdom, with research, clinical development, and corporate functions integrated across these regions. KalVista controls its proprietary small-molecule drug design technology and manages global clinical trials through a combination of internal teams and external contract research organizations. As of publicly available disclosures, the company does not report material revenue-generating partnerships or joint ventures, but it does maintain standard industry collaborations with academic institutions and clinical research providers.
Strategic Position & Investments
KalVista’s strategic direction is focused on advancing sebetralstat toward regulatory approval and potential commercialization as a differentiated oral, on-demand therapy for HAE, positioning it against injectable alternatives currently on the market. The company’s growth strategy emphasizes clinical execution, regulatory readiness, and the potential expansion of its kallikrein inhibition platform into additional indications.
Investment activity has primarily taken the form of internal R&D spending rather than acquisitions, with capital allocated to late-stage clinical trials, manufacturing scale-up, and regulatory preparation. KalVista has not announced any major transformative acquisitions, and its pipeline remains internally developed. Emerging opportunities are centered on expanding the application of its protease inhibitor technology beyond HAE, although these programs remain at earlier stages of development based on publicly available information.
Geographic Footprint
KalVista maintains its corporate headquarters in the United States, with a significant operational presence in the United Kingdom, reflecting its origins and continued R&D activities. The company’s clinical trials are conducted across multiple regions, including North America and Europe, supporting a global regulatory strategy.
While KalVista does not yet have a commercial sales footprint, its international clinical and regulatory activities provide it with operational exposure across key pharmaceutical markets. The company’s geographic influence is primarily research- and development-driven rather than revenue-based at this stage.
Leadership & Governance
KalVista is led by an executive team with experience in rare disease drug development, clinical execution, and public company governance. The leadership’s stated strategic vision emphasizes disciplined clinical development, scientific rigor, and addressing unmet needs in rare diseases through patient-friendly therapies.
Key executives include:
- Andrew Crockett – Chief Executive Officer
- Ben Palleiko – Chief Financial Officer
- Paul Audhya – Chief Medical Officer
- David Horn Solomon – President and Founder
The company operates under a standard U.S. public company governance structure, with oversight provided by a board of directors comprising executives and independent members with backgrounds in biotechnology, finance, and pharmaceutical development.